A Phase I, Placebo-controlled, Randomized, Double Blind, Single or Multiple Dose Study of URC102 in Healthy Male Volunteers of Korean and Caucasian to Assess Safety, Pharmacokinetics and Pharmacodynamics
Phase of Trial: Phase I
Latest Information Update: 10 Mar 2017
At a glance
- Drugs URC 102 (Primary)
- Indications Gout
- Focus Adverse reactions
- Sponsors JW Pharmaceutical
- 06 Mar 2017 Status changed from active, no longer recruiting to completed.
- 12 May 2014 Planned end date changed from 1 Apr 2014 to 1 Jun 2014 as reported by ClinicalTrials.gov.
- 12 May 2014 Trial status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.